Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 5/20 | 0.62 |
| ▸ | PRKCG | P05129 | 5/20 | 0.62 |
| ▸ | PRKD3 | O94806 | 4/20 | 0.62 |
| ▸ | PRKCB | P05771 | 4/20 | 0.62 |
| ▸ | PRKCH | P24723 | 4/20 | 0.62 |
| ▸ | PRKCI | P41743 | 4/20 | 0.62 |
| ▸ | PRKCE | Q02156 | 4/20 | 0.62 |
| ▸ | PRKCQ | Q04759 | 4/20 | 0.62 |
| ▸ | PRKCZ | Q05513 | 4/20 | 0.62 |
| ▸ | PRKCD | Q05655 | 4/20 | 0.62 |
| ▸ | PRKD1 | Q15139 | 4/20 | 0.62 |
| ▸ | USP2 | O75604 | 2/20 | 0.62 |
| ▸ | TP53 | P04637 | 2/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phorbol SCHEMBL28866474 | 1.00 | PRKCA (0.62) | PRKCAPRKCGPRKD3PRKCBPRKCH | |
| Phorbol SCHEMBL27419386 | 1.00 | PRKCA (0.62) | PRKCAPRKCGPRKD3PRKCBPRKCH | |
| Phorbol SCHEMBL22973790 | 1.00 | PRKCA (0.62) | PRKCAPRKCGPRKD3PRKCBPRKCH | |
| Phorbol SCHEMBL27299282 | 0.98 | PRKCA (0.63) | PRKCAPRKCGPRKD3PRKCBPRKCH | |
| Phorbol SCHEMBL27478115 | 0.94 | PRKCA (0.60) | PRKCAPRKCGPRKD3PRKCBPRKCH | |
| Phorbol SCHEMBL28465138 | 0.94 | PRKCA (0.56) | PRKCAPRKCGPRKD3PRKCBPRKCH | |
| Phorbol SCHEMBL27450792 | 0.93 | PRKCA (0.62) | PRKCAPRKCGPRKD3PRKCBPRKCH | |
| Phorbol SCHEMBL23610504 | 0.92 | PRKCA (0.61) | PRKCAPRKCGPRKD3PRKCBPRKCH | |
| Phorbol SCHEMBL27579226 | 0.92 | PRKCA (0.67) | PRKCAPRKCGPRKD3PRKCBPRKCH | |
| Phorbol SCHEMBL7566989 | 0.92 | PRKCA (0.60) | PRKCAPRKCGPRKD3PRKCBPRKCH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 539 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030124524-A1 | Screening assays for identifying modulators of the inflammatory or immune response | ORIG3N, INC. | 2003-07-03 | — | — | US | claimed |
| WO-2002000933-A2 | SCREENING ASSAYS FOR IDENTIFYING MODULATORS OF THE INFLAMMATORY OR IMMUNE RESPONSES | INTERLEUKIN GENETICS, INC. (US) | 2002-01-03 | — | — | WO | claimed |
| CN-1233171-A | Inhibition of nuclear transcription factor NF- κ B by Caffeic Acid Phenethyl Ester (CAPE), CAPE derivatives, capsaicin (8-methyl-N-vanillyl-6-nonenamide) and resiniferatoxin | RES DEV FOUNDATION (US) | 1999-10-27 | — | — | CN | claimed |
| US-20260130939-A1 | PRODUCTION AND USE OF NATURAL KILLER (NK) CELL-DERIVED EXTRACELLULAR VESICLES FOR TREATMENT OF CANCER AND INFECTIOUS DISEASE | SAINT LOUIS UNIVERSITY (US) | 2026-05-14 | — | — | US | disclosed |
| US-20250352608-A1 | POLYPEPTIDES HAVING ANTI-INFLAMMATORY EFFECTS AND USES THEREOF | ONESKIN INC (US) | 2025-11-20 | — | — | US | disclosed |
| US-20250270284-A1 | MHC Class II Protein Constructs | CUE BIOPHARMA INC (US) | 2025-08-28 | — | — | US | disclosed |
| EP-4547706-A1 | MHC CLASS II PROTEIN CONSTRUCTS | Cue Biopharma, Inc. (US) | 2025-05-07 | — | — | EP | disclosed |
| US-12246046-B2 | Compositions and methods for the treatment of type 1 diabetes | INTREXON ACTOBIOTICS N.V. (BE) | 2025-03-11 | — | — | US | disclosed |
| US-20240082323-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF TYPE 1 DIABETES | INTREXON ACTOBIOTICS N.V. (BE) | 2024-03-14 | — | — | US | disclosed |
| US-20240050344-A1 | Methods of Enhancing Natural Defense in the Oral Cavity | COLGATE-PALMOLIVE COMPANY (US) | 2024-02-15 | — | — | US | disclosed |
| EP-3919065-B9 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF TYPE 1 DIABETES | INTREXON ACTOBIOTICS NV (BE) | 2024-01-24 | — | — | EP | disclosed |
| WO-1992005760-A1 | METHOD AND COMPOSITIONS FOR DIAGNOSING AND TREATING CHRONIC FATIGUE IMMUNODYSFUNCTION SYNDROME | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 1992-04-16 | — | — | WO | disclosed |
| US-5078999-A | Administering rapamycins | AMERICAN HOME PRODUCTS CORPORATION (US) | 1992-01-07 | — | — | US | disclosed |
| WO-1991015226-A1 | REJUVENATION COMPOSITIONS AND METHODS FOR THEIR USE | THE AMERICAN NATIONAL RED CROSS (US) | 1991-10-17 | — | — | WO | disclosed |
| WO-1990012590-A1 | TREATMENT OF OCULAR DISEASE BY MODULATION OF MATRIX METALLOPROTEINASES AND THEIR INHIBITOR | STATE OF OREGON, STATE BOARD OF HIGHER EDUCATION, OREGON HEALTH SCIENCES UNIVERSITY (US) | 1990-11-01 | — | — | WO | disclosed |
| EP-0394409-A1 | MACROPHAGE-DERIVED INFLAMMATORY MEDIATOR (MIP-2). | UNIV ROCKEFELLER (US) | 1990-10-31 | — | — | EP | disclosed |
| WO-1990002762-A1 | MACROPHAGE-DERIVED INFLAMMATORY MEDIATOR (MIP-2) | THE ROCKEFELLER UNIVERSITY (US) | 1990-03-22 | — | — | WO | disclosed |
| EP-0198014-A4 | VECTORS CONTAINING A GENE FOR A PROTEIN HAVING ERYTHROID-POTENTIATING ACTIVITY AND RECOMBINANT DNA METHODS FOR PRODUCING SAID PROTEIN. | SANDOZ LTD (CH) | 1987-11-23 | — | — | EP | disclosed |
| EP-0198014-A1 | VECTORS CONTAINING A GENE FOR A PROTEIN HAVING ERYTHROID-POTENTIATING ACTIVITY AND RECOMBINANT DNA METHODS FOR PRODUCING SAID PROTEIN | SANDOZ LTD. (CH) | 1986-10-22 | — | — | EP | disclosed |
| WO-1986002100-A1 | VECTORS CONTAINING A GENE FOR A PROTEIN HAVING ERYTHROID-POTENTIATING ACTIVITY AND RECOMBINANT DNA METHODS FOR PRODUCING SAID PROTEIN | SANDOZ LTD. (CH) | 1986-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260130939-A1 | PRODUCTION AND USE OF NATURAL KILLER (NK) CELL-DERIVED EXTRACELLULAR VESICLES FOR TREATMENT OF CANCER AND INFECTIOUS DISEASE | PBK, KLRK1, CD4 | PRKCA 138/4885PRKCG 107/4885PRKD3 320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.